Profile data is unavailable for this security.
About the company
Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. It organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
- Revenue in EUR (TTM)5.21bn
- Net income in EUR65.56m
- Incorporated1987
- Employees27.58k
- LocationGrifols SAC/ Jesus y Maria, 6BARCELONA 08022SpainESP
- Phone+34 935710000
- Fax+34 935710267
- Websitehttps://www.grifols.com/en/web/gcom
More ▼
Mergers & acquisitions
| Acquired company | GRF:MCE since announced | Transaction value |
|---|---|---|
| Prometic Plasma Resources Inc-Donation Center | -38.92% | 3.14m |
Data delayed at least 15 minutes, as of Dec 09 2022 16:10 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Krka d.d. Novo Mesto | 1.63bn | 369.41m | 3.09bn | 11.49k | 7.93 | 1.39 | 6.72 | 1.89 | 11.87 | 11.87 | 52.44 | 67.81 | 0.644 | 1.44 | 3.50 | 141,729.90 | 14.60 | 11.07 | 17.28 | 13.24 | 55.63 | 57.68 | 22.66 | 16.24 | 2.27 | -- | 0.0054 | 56.25 | 2.01 | 5.92 | 6.26 | 23.31 | -9.89 | 15.41 |
| BB BIOTECH AG | -312.62m | -878.75m | 3.26bn | -- | -- | 1.17 | -- | -- | -15.67 | -15.67 | -5.60 | 49.62 | -0.0868 | -- | -- | -- | -24.39 | 6.67 | -26.50 | 7.00 | -- | 99.75 | -- | 63.36 | -- | -0.6996 | 0.1002 | 80.76 | -146.32 | -- | -158.57 | -- | -- | 6.96 |
| Abcam Plc | 406.94m | 7.90m | 3.37bn | 1.75k | 428.09 | 3.98 | 53.02 | 8.28 | 0.0296 | 0.0296 | 1.53 | 3.18 | 0.371 | 1.85 | 6.49 | 200,228.60 | 0.7199 | -- | 0.8403 | -- | 72.69 | -- | 1.94 | -- | 0.9828 | 23.46 | 0.2401 | -- | -- | -- | -- | -- | -- | -- |
| Dechra Pharmaceuticals plc | 791.81m | 67.59m | 3.54bn | 2.04k | 50.09 | 4.35 | 20.78 | 4.47 | 0.5342 | 0.5342 | 6.26 | 6.15 | 0.5438 | 1.82 | 5.60 | 334,872.30 | 4.64 | 3.55 | 5.31 | 4.00 | 56.51 | 56.74 | 8.54 | 7.22 | 1.69 | 24.89 | 0.3305 | 96.35 | 12.14 | 13.67 | 4.86 | 17.39 | 48.50 | 15.93 |
| Dottikon ES Holding AG | 287.21m | 75.17m | 3.63bn | 670.00 | 47.58 | 4.68 | 37.96 | 12.62 | 5.38 | 5.38 | 20.55 | 54.73 | 0.3166 | 0.4641 | 5.14 | 426,878.20 | 8.29 | 6.73 | 9.67 | 7.56 | 75.59 | 81.91 | 26.17 | 19.64 | 1.78 | -- | 0.0383 | -- | 15.09 | 10.67 | 13.33 | 21.75 | 23.13 | -- |
| Richter Gedeon Vegyeszeti Gyar Nyrt | 1.82bn | 583.01m | 3.86bn | 12.18k | 6.62 | 1.46 | 5.49 | 2.13 | 1,301.43 | 1,301.43 | 4,051.99 | 5,896.20 | 0.6043 | 2.16 | 3.84 | 61,577,310.00 | 19.55 | 7.87 | 22.61 | 8.95 | 57.45 | 55.98 | 32.36 | 13.18 | 2.53 | -- | 0.0156 | 37.82 | 11.26 | 10.10 | 33.38 | 16.10 | 31.49 | 16.23 |
| Hikma Pharmaceuticals Plc | 2.42bn | 328.48m | 3.89bn | 8.70k | 12.43 | 1.88 | 7.77 | 1.61 | 1.22 | 1.22 | 9.02 | 8.08 | 0.5713 | 1.65 | 3.45 | 239,517.80 | 7.75 | 3.80 | 9.99 | 5.21 | 51.29 | 50.90 | 13.57 | 6.61 | 1.37 | 8.36 | 0.4145 | 71.43 | 9.06 | 5.54 | -2.32 | 22.12 | 3.80 | 11.07 |
| Swedish Orphan Biovitrum AB (publ) | 1.63bn | 229.63m | 6.03bn | 1.56k | 25.23 | 2.49 | 12.88 | 3.70 | 8.37 | 8.37 | 59.39 | 84.68 | 0.3624 | 1.37 | 5.59 | 11,350,870.00 | 5.10 | 8.45 | 6.18 | 10.61 | 74.66 | 76.41 | 14.08 | 21.08 | 0.5223 | 9.07 | 0.2889 | 0.00 | 1.76 | 24.44 | -17.44 | 27.31 | 17.53 | -- |
| Grifols SA | 5.21bn | 65.56m | 6.17bn | 27.58k | 105.90 | 1.07 | 11.88 | 1.19 | 0.0942 | 0.0942 | 7.56 | 9.32 | 0.2795 | 1.30 | 8.91 | 224,102.70 | 0.7482 | 4.23 | 0.9347 | 5.15 | 36.90 | 44.51 | 2.68 | 12.07 | 0.9051 | 2.92 | 0.5401 | 26.75 | -7.62 | 4.02 | -71.29 | -19.12 | 1.49 | -- |
| BACHEM HOLDING AG | 504.83m | 99.33m | 6.39bn | 1.66k | 63.13 | 5.69 | 49.06 | 12.67 | 1.36 | 1.36 | 6.88 | 15.07 | 0.4918 | 1.19 | 5.83 | 304,439.30 | 9.68 | 9.82 | 11.64 | 12.30 | 31.55 | 31.43 | 19.68 | 19.02 | 4.06 | 13.64 | 0.0006 | 63.76 | 25.18 | 16.30 | 46.91 | 22.72 | 18.43 | 6.96 |
| Orion Oyj | 1.32bn | 350.70m | 7.09bn | 3.53k | 20.18 | 7.26 | 18.04 | 5.36 | 2.49 | 2.49 | 9.40 | 6.92 | 1.01 | 1.63 | 8.28 | 394,217.60 | 26.73 | 18.94 | 31.63 | 23.82 | 64.06 | 59.52 | 26.52 | 19.89 | 2.26 | -- | 0.1812 | 101.61 | -3.44 | -0.613 | -11.87 | -4.89 | 12.25 | -0.6537 |
| DiaSorin SpA | -100.00bn | -100.00bn | 7.26bn | 3.35k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 16.63 | -- | 19.02 | -- | 67.86 | -- | 24.99 | -- | -- | -- | 25.24 | 40.43 | 16.80 | 25.46 | 22.58 | 25.68 | 5.59 |
| Recordati Industria Chimica e Farma SpA | 1.80bn | 331.04m | 8.47bn | 4.30k | 25.46 | 5.17 | 18.99 | 4.70 | 1.59 | 1.59 | 8.65 | 7.84 | 0.5216 | 1.66 | 5.19 | 418,644.40 | 9.59 | 14.35 | 12.00 | 18.15 | 70.16 | 71.34 | 18.38 | 23.93 | 1.08 | 11.55 | 0.5136 | 59.22 | 9.06 | 6.49 | 8.73 | 10.21 | 34.74 | 9.46 |
| Ipsen SA | 3.08bn | 725.60m | 8.98bn | 5.74k | 12.28 | 2.88 | 9.31 | 2.91 | 8.72 | 8.85 | 37.05 | 37.15 | 0.6147 | 2.50 | 5.23 | 536,629.50 | 14.50 | 9.53 | 19.31 | 13.46 | 82.82 | 81.50 | 23.60 | 14.05 | 1.75 | 50.37 | 0.1927 | 22.45 | 11.65 | 12.41 | 18.82 | 23.42 | 2.81 | 7.14 |
Data as of Dec 09 2022. Currency figures normalised to Grifols SA's reporting currency: Euro EUR
15.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2022 | 19.88m | 4.67% |
| The Vanguard Group, Inc.as of 31 Oct 2022 | 8.10m | 1.90% |
| Norges Bank Investment Managementas of 31 Dec 2021 | 7.42m | 1.74% |
| BlackRock Fund Advisorsas of 03 Nov 2022 | 6.54m | 1.54% |
| Jupiter Asset Management Ltd.as of 31 Aug 2022 | 5.53m | 1.30% |
| LGT Capital Partners AG (Investment Management)as of 31 May 2022 | 5.01m | 1.18% |
| DWS Investment GmbHas of 03 Nov 2022 | 4.52m | 1.06% |
| BNP Paribas Asset Management France SASas of 31 Oct 2022 | 3.65m | 0.86% |
| Geode Capital Management LLCas of 01 Dec 2022 | 3.26m | 0.77% |
| Capital International Ltd.as of 03 Nov 2022 | 3.11m | 0.73% |
More ▼
Data from 31 Dec 2021 - 30 Sep 2022Source: FactSet Research Systems Inc.
